Evidence map›Paper›PMID 38505718›Full record

ArticleNagoya journal of medical science2024

Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer.

Koki Nakanishi, Chie Tanaka, Mitsuro Kanda, Kazushi Miyata, Nozomu Machida, Mitsuru Sakai, Daisuke Kobayashi, Hitoshi Teramoto, Akiharu Ishiyama, Bin Sato and 17 more

Open access · greenAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Nagoya journal of medical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 13 institutions in 1 country.

Koki NakanishiDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Chie TanakaDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Mitsuro KandaDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kazushi MiyataDivision of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Nozomu MachidaDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Mitsuru SakaiDepartment of Surgery, Ichinomiya Municipal Hospital, Ichinomiya, Japan.
Daisuke KobayashiDepartment of Surgery, Komaki City Hospital, Komaki, Japan.
Hitoshi TeramotoDepartment of Surgery, Yokkaichi Municipal Hospital, Yokkaichi, Japan.
Akiharu IshiyamaDepartment of Surgery, Okazaki City Hospital, Okazaki, Japan.
Bin SatoDepartment of Surgery, Kainan Hospital, Yatomi, Japan.
Takashi OshimaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Masaki KajikawaDepartment of Surgery, Gifu Prefectural Tajimi Hospital, Tajimi, Japan.
Hidenobu MatsushitaDepartment of Surgery, Tosei General Hospital, Seto, Japan.
Kiyoshi IshigureDepartment of Surgery, Konan Kosei Hospital, Konan, Japan.
Katsuya YamashitaDepartment of Surgery, Toyohashi Medical Center, Toyohashi, Japan.
Shinichi FujitakeDepartment of Surgery, Nishio Municipal Hospital, Nishio, Japan.
Satoshi SueokaDepartment of Surgery, Ichinomiya Municipal Hospital, Ichinomiya, Japan.
Takahiro AsadaDepartment of Surgery, Gifu Prefectural Tajimi Hospital, Tajimi, Japan.
Dai ShimizuDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Shizuki SugitaDivision of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yachiyo KuwatsukaDepartment of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
Osamu MaedaDepartment of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.
Satoshi FuruneDepartment of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.
Kenta MurotaniThe Biostatistics Center, Graduate School of Medicine, Kurume University, Kurume, Japan.
Yuichi AndoDepartment of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.
Tomoki EbataDivision of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yasuhiro KoderaDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Nagoya University · JPNagoya University Hospital · JPGifu Prefectural Tajimi Hospital · JPIchinomiya Municipal City Hospital · JPKanagawa Cancer CenterKanagawa Prefectural Hospital Organization · JPKinan Hospital · JPKomaki City Hospital · JPKonan Kosei Hospital · JPOkazaki City Hospital · JPTosei General Hospital · JPToyohashi Heart Center · JPYokkaichi Municipal Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In Japan, systemic chemotherapy is the standard treatment for unresectable, advanced, or recurrent gastric cancer. However, numerous patients with gastric cancer do not receive late-line treatment because of the rapid progression of gastric cancer. Additionally, late-line treatments, such as nivolumab, trifluridine tipiracil (FTD/TPI), or irinotecan, have limited effects on improving clinical symptoms and delaying the onset of symptoms associated with cancer progression. Recently, a combination of FTD/TPI and ramucirumab was reported to have a high response rate in late-line treatment; however, owing to patient selection bias and a high rate of hematologic toxicity in that previous study, this regimen may not be feasible in real-world clinical applications. Our objective is to conduct a single-arm phase II study to assess the safety and efficacy of FTD/TPI plus ramucirumab combination therapy for gastric cancer after third-line treatment under real-world clinical conditions. This study will recruit 32 patients according to eligibility criteria and administer FTD/TPI (35 mg/m

Indexed as

Frontotemporal DementiaPyrrolidinesStomach NeoplasmsThymineAntineoplastic Combined Chemotherapy ProtocolsClinical Trials, Phase II as TopicDrug CombinationsHumansNeoplasm Recurrence, LocalRamucirumabTrifluridineDrug CombinationsPyrrolidinesRamucirumabThyminetipiracilTrifluridinetrifluridine tipiracil drug combinationclinical trialgastric cancerramucirumabtrifluridine tipiracil

Identifiers

PMID38505718
PMCPMC10945229
OpenAlexW4394767370

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.